Janssen Promoted Risperdal Off Label, Jury Hears

Law360, Philadelphia (September 25, 2012, 8:40 PM EDT) -- Ortho-McNeil-Janssen Pharmaceuticals Inc. directed its salespeople to push the antipsychotic drug Risperdal for mood and behavioral disorders in children despite the risk male patients might grow breasts as a side effect, a former regional manager for the company told a jury Tuesday.

Tone Jones, a former sales manager with Janssen, testified in Pennsylvania state court as part of a case brought by Texas teenager Andrew Bentley, who claims off-label use of Risperdal led to his gynecomastia, which is the abnormal development of mammary glands in males....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.